BICYCLE THERAPEUTICS PLC
BCYC · XNASCIK 1761612fmd_161K8X4BS3AK4KP0VN9ESY7MPKManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 36 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 2 | 7 | 14 | 10 | 12 | 14 | 27 | 35 | 73 |
| Research and development | 12 | 21 | 26 | 33 | 45 | 82 | 156 | 173 | 240 |
| Total operating expenses | 18 | 29 | 40 | 62 | 77 | 131 | 217 | 245 | 320 |
| Operating income | (16) | (22) | (26) | (52) | (66) | (117) | (190) | (210) | (247) |
| Interest expense | – | – | – | 0 | 3 | 3 | 3 | 2 | 0 |
| Interest and investment income | 0 | 0 | 1 | 1 | 0 | 6 | 14 | 34 | 28 |
| Other non-operating income (expense) | (0) | (0) | (5) | 0 | (3) | 2 | 11 | 36 | 28 |
| Income before taxes | (16) | (22) | (31) | (52) | (68) | (114) | (179) | (174) | (219) |
| Income tax expense | (0) | (0) | (0) | (1) | (2) | (2) | 1 | (5) | 0 |
| Net income from continuing operations | (16) | (22) | (31) | (51) | (67) | (113) | (181) | (169) | (219) |
| Net income | (16) | (22) | (31) | (51) | (67) | (113) | (181) | (169) | (219) |
| Net income to common shareholders | (16) | (22) | (31) | (51) | (67) | (113) | (181) | (169) | (219) |